ARASENS Trial Videos

Practice Changing Data from ARASENS - Statistically Significant Overall Survival - Fred Saad, Bertrand Tombal, and Neal Shore

Details
Fred Saad, Bertrand Tombal, and Neal Shore join Alicia Morgans in a discussion on the results of the ARASENS trial which examined darolutamide in combination with docetaxel and ADT compared to docetaxel and ADT. They discuss the trial design, its endpoints, how it impacts practice in Canada, the US, and in Europe, and the ideal patient population for this treatment. Biographies: Neal Shore, MD, FA...

ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen highlight the New England Journal of Medicine publication on the international, phase 3 ARASENS trial. The primary analysis involved 1306 patients (651 in the darolutamide group and 655 in the placebo group); 86.1% of the patients had disease that was metastatic at the time of the initial diagnosis. At the data cutoff date for the primary analysis (October 2...

ARASENS Trial Significantly Improves Overall Survival with Darolutamide in Combination with ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith

Details
Joining Alicia Morgans is Matthew Smith to discuss the ARASENS trial presented at GU ASCO 2022. ARASENS is a randomized phase 3 trial of darolutamide versus placebo in combination with docetaxel and androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Smith believes that the ARASENS data strongly supports a three-drug regimen of ADT, docetaxel, and an AR...

Advanced Prostate Cancer Practice Informing Data Presented at ASCO GU 2022 - Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans to reflect on prostate cancer data presented during ASCO GU, highlighting data from three studies. Dr. Sartor discusses the phase 3 ARASENS trial, the phase 3 MAGNITUDE study, and the phase 3 PROpel trial. They discuss their perspectives on how these data will inform practice in the future. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Dire...

Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi

Details
Karim Fizazi joins Alicia Morgans in discussing the ARASENS trial which examined darolutamide in combination with docetaxel and androgen deprivation therapy (ADT) compared to docetaxel and ADT. The ARASENS trial is an international, double-blind, phase 3 study that enrolled patients with mHSPC and ECOG performance status 0 or 1. Drs. Morgans and Fizazi detail the overall survival data presented at...
email news signup